NUTEX Investments Public Limited Company Overview
NUTEX is a former Hungarian pharmaceutical research company — originally HUMET, developer of the humic/fulvic-acid trace-element preparation HUMET-R — that has transformed over the past decade into a cash-rich, operationally dormant listed investment holding company. It no longer manufactures or sells products; its sole operating revenue (HUF 0.45 M in FY2025) comes from leasing fully amortised intangible assets to a single Hungarian counterparty. Its economic value lies in a balance sheet of roughly HUF 6.1 bn (30 June 2026) composed almost entirely of cash (EUR, USD and HUF deposits), liquid Budapest-listed equities (dominated by OTP Bank), Hungarian government securities and units of an Erste euro real-estate fund, with no debt. Hungarian financial media describe it as an "empty" listed shell that could serve as a reverse-listing vehicle. Management's stated strategy is acquisitive, and since 2025 it has built a holding/acquisition subsidiary chain, but no acquisition has yet closed. The shares trade at roughly one-third of book value.
The company's own description (2025 Annual Report and H1 2026 Report)
In its FY2025 consolidated management report, NUTEX describes itself as having operated throughout 2025 essentially as a company managing its own assets, whose activity consists of managing and coordinating its assets and investments. It continued to lease out its intangible assets, invested part of its cash in liquid securities (mainly Budapest-listed shares and Hungarian government securities), and held significant EUR and USD bank deposits plus investment units of the Erste Open-ended Euro Real Estate Investment Fund. The company states that it repaid its former long-term debt in full in earlier years and that, under its acquisition strategy, it examined new acquisition opportunities during the year, none of which had been completed.
The stated corporate purpose (H1 2026 Report, Note 1) is to manage the group's assets, ensure the sustainability of group members and increase shareholder value. The strategy includes shaping the investment portfolio through new company formation or acquisitions, and possibly reorganising, selling or realising existing holdings; promoting geographic expansion of investments; and exploiting intangible assets through leasing. The company notes that its investments were historically concentrated on human-health-related businesses, but that other types of investment may also feature in its strategy.
Independent characterisation
| Business-model dimension | Assessment |
|---|---|
| Revenue model | Licensing/leasing of intangible assets (100% of revenue; one Hungarian counterparty). No product, service or subscription revenue |
| Economic earnings model | Investment income: fair-value gains on listed equities, dividends, interest; FX gains/losses |
| Value-chain position | None in an operating sense; capital allocator / holding company |
| Customer types | One related or unrelated licensee (identity not disclosed) |
| End-markets | Effectively Hungarian capital markets (OTP, MOL, Richter shares; Hungarian government bonds) and euro-area real estate (via Erste fund) |
| Revenue mix (FY2025) | Licensing 100%; product 0%; service 0%; subscription 0% |
NUTEX is, in substance, a listed cash-and-securities shell with an acquisition mandate. Its income statement is driven almost entirely by mark-to-market movements on its securities portfolio (above all OTP Bank shares), dividends received, and foreign-exchange revaluation of its EUR/USD deposits. Operating costs (HUF 108.9 M SG&A in FY2025) are dominated by non-cash IFRS 2 share-based payment charges linked to its Employee Share Ownership Programme (MRP), rather than by an operating business.
Interpretive note: Because the revenue line is immaterial (HUF 0.45 M), conventional revenue-based metrics (margins, EV/Sales, revenue CAGR) are not meaningful. The appropriate analytical lens is that of a closed-end holding company: net asset value (NAV), the composition and risk of the asset base, cost drag on NAV, governance and capital-allocation discipline, and the probability and quality of a transformative acquisition.
Strategy
Stated strategic themes (paraphrased from FY2025 Annual Report and H1 2026 Report)
-
Asset stewardship and shareholder value: manage group assets, ensure sustainability of group members and increase shareholder value.
-
Portfolio construction through acquisitions or new companies: expand the investment portfolio by founding companies or acquiring them; reorganise, sell or realise existing holdings as appropriate.
-
Geographic expansion of investments and improvement of their markets.
-
Exploitation of intangible assets through leasing.
-
Preservation of the investor structure (the company repeatedly states it intends to maintain its investor structure).
-
Sector-agnostic broadening: historically health-focused, but other investments and activities may be pursued if they serve the company's interests.
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| NT Asset Management Kft. | Founded 27 Jan 2025 | Wholly owned holding subsidiary (HUF 300 M) to manage assets | Capitalised to HUF 5,218 M by Jul 2026; holds OTP shares |
| Asset transfers into NT AM | Dec 2025–May 2026 | HUF 1,747 M + 1,845 M + 1,323 M cash injections; OTP shares sold to NT AM (31 Mar 2026); shareholder support for transferring the Erste fund units (20 May 2026) | Ongoing |
| NT Valoris Kft. acquisition vehicle | 7 Jul 2026 | New Kft. dedicated to acquisitions; intended later conversion to a private Zrt.; managers may take up to 5% | Founded; capital increases Aug and Oct 2026 |
| MRP expansion | Jan 2025–Jun 2026 | See Section 9.3 | Ongoing; ≥32 M further shares authorised |
| Capital-raising authorisations | Apr–Jun 2026 | Board authorised to raise capital up to HUF 60–70 bn through 2031 (and a further authorisation window to 2036), including preference shares; issue price for ordinary shares at least the last closing price | Authorised, unused except MRP placement |
| Voting-preference share programme | 26 Jun 2026 | New unlisted voting-preference shares (up to 10x votes) at 1.5x last close, with company call option | Authorised |
| Treasury share authorisations | Apr–Jun 2026 | Board may hold up to 25% of share capital in own shares for 18 months; price ceiling 1.5x book value per share (ordinary) or 10x (preference) | Authorised; no purchases since last AGM |
| Acquisition screening | 2025–2026 | Company examined acquisition opportunities; none completed | No transaction announced |
Cost programmes / ESG commitments
No cost-reduction programmes or ESG/sustainability commitments have been announced.
Medium-term targets / guidance
NUTEX provides no financial guidance and no medium-term targets. The H1 2026 report's going-concern statement says current assets cover operating costs and the group's operation is secured on the basis of its future plans.
Analyst interpretation: The scale of capital authorisations (up to HUF 70 bn versus current equity of ≈ HUF 6.1 bn) and the creation of a dedicated acquisition vehicle signal that management is preparing for a transaction that could be an order of magnitude larger than the current company — i.e., a reverse-listing or contribution-in-kind deal that would transform NUTEX. The terms of any such deal (valuation, dilution, voting structure) will determine whether existing minority shareholders benefit.
Products & Services
NUTEX currently has no commercial product or service portfolio. The catalogue below distinguishes the current asset-based "offering" from the historic product lines that some data aggregators still attribute to the company.
Current activities (single segment)
| Line | Description | Customer | Status | Pricing |
|---|---|---|---|---|
| Intangible-asset leasing | Lease of intangible assets (gross book value HUF 58.6 M, fully amortised to zero) | One Hungarian counterparty (not named) | Active; HUF 0.45 M revenue FY2024 and FY2025 | — |
| Proprietary securities portfolio | Listed equities (OTP, MOL, Richter), Hungarian government bonds and discount T-bills | Not applicable (own account) | Active | Not applicable |
| Real-estate fund units | Erste Open-ended Euro Real Estate Investment Fund units (EUR-denominated) | Not applicable | HUF 548.3 M at YE2025 | Not applicable |
| FX deposits | Significant EUR and USD deposits | Not applicable | EUR ≈ HUF 1,451 M and USD ≈ HUF 262 M at YE2025 (derived from ±10% sensitivity disclosures) | Not applicable |
Historic product lines (no longer operated by NUTEX)
| Product / brand | Description | Launch | Status |
|---|---|---|---|
| HUMET-R | Medicinal product containing the Humifulvát (humic/fulvic acid) active ingredient; trace-element preparation | 1,994 | The BÉT profile still lists this as the main activity, but the company's own filings describe pure asset management; no product sales in FY2024–FY2025 |
| Enerex (dietary supplements) | Supplement brand of Canada's Enerex Botanicals Ltd., in which subsidiary HUMET North America held 70.7% in 2012 | — | Attributed by aggregators (Musaffa, Erste Market) to the former "Nutex Group"; not consolidated in any period reviewed (2023–2026) |
| Organic Mission | Health/cosmetics brand attributed to the former Nutex Group by aggregators | — | Not consolidated in the period reviewed |
| Former markets | Aggregators list Hungary, Slovakia, UK, Canada, Taiwan, Iran, UAE, Mexico and Hong Kong | — | Outdated; current revenue is 100% Hungarian |
Financial Narrative
Basis of preparation: FY2024–FY2025 are audited consolidated IFRS (2025 Annual Report). FY2022–FY2023 are from the 2023 Annual Report (IFRS; the company had no subsidiary in those years, so figures are effectively standalone). FY2021 figures were not available in the sources reviewed. H1 figures are unaudited.
Income statement
Note: no dividend was declared after FY2023 (AGM April 2024), FY2024 (AGM 23 April 2025) or FY2025 (AGM 28 April 2026).
Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue is HUF 0.45 M; arithmetically, FY2025 net income is roughly 1,100x revenue and the operating margin is approximately -24,900%. Revenue CAGR cannot be computed over five years; FY2024–FY2025 growth is 0%.
Financial-result composition
In the FY2024 and FY2025 cash-flow statements, dividends received appear as HUF 74.9 M and HUF 70.2 M respectively; interest received is HUF 3.3 M and HUF 18.2 M. The company attributes financial income mainly to value increases in listed shares (primarily OTP) and financial expenses mainly to unrealised FX losses on year-end revaluation of foreign-currency assets.
Interim trend
H1 2026 net income of HUF 517.7 M already exceeds full-year FY2025 (HUF 494.2 M). Trailing-twelve-month (TTM) net income to 30 June 2026 is ≈ HUF 896.5 M (derived: FY2025 494.2 − H1 2025 115.4 + H1 2026 517.7).
Balance sheet
At 30 June 2026: total assets HUF 6,103.8 M; cash HUF 2,327.7 M; short-term investments HUF 3,535.5 M; current liabilities HUF 9.5 M; equity HUF 6,094.3 M (of which attributable to parent HUF 6,090.8 M); no debt.
Asset composition at 31 December 2025
Between YE2024 and YE2025, Level 1 equity holdings rose from HUF 1,463.0 M to HUF 2,325.0 M while government securities fell from HUF 839.4 M to HUF 247.3 M — a deliberate rotation from sovereign debt into equities (largely OTP) that raised portfolio risk materially. MOL holdings were HUF 55.3 M at YE2023 (2023 Annual Report).
Cash flow
H1 2026: operating cash flow HUF -0.05 M; investing cash flow HUF +74.2 M (dividends HUF 73.6 M, interest HUF 1.0 M, capex HUF -0.4 M); financing HUF 0; net change in cash HUF +74.2 M. Operating cash flow is distorted because purchases/sales of trading securities run through working-capital lines ("other current assets").
Ratios
ROIC, net debt/EBITDA and interest coverage are not meaningful (negative EBITDA, no invested operating capital, no interest expense). The cash conversion cycle is not applicable (no inventory; trade receivables HUF 0 at YE2025). The H1 2026 report shows liabilities/equity of 0.16% and pre-tax profit/equity of 8.50% for the half-year.
Per-share and NAV metrics
Discrepancy note: Világgazdaság (January 2026), citing BÉT data, reported equity per share "above HUF 31"; the derived figures above (HUF 33.5–35.6) are higher. The difference likely reflects whether MRP-held shares are excluded and which reporting date is used. Note also that the 2025 Annual Report shows the 2024 weighted average share count as 149,046,381 in one table and 146,046,381 in another — an internal inconsistency in the filing.
Commentary on trends, inflections and drivers
Earnings are a function of the OTP share price, not of operations. Net income rose from HUF 133.5 M (FY2022) to HUF 171.1 M (FY2023), HUF 423.4 M (FY2024) and HUF 494.2 M (FY2025), then HUF 517.7 M in H1 2026 alone. Each step-up coincides with strong performance of Budapest bank equities; the company itself states that the positive financial result came mostly from unrealised gains on revaluing its liquid listed shares (mainly OTP). H1 2023's loss (HUF -24.8 M) shows the downside sensitivity when markets fall.
The cost base is rising in a non-cash way. SG&A rose from HUF 97.1 M to HUF 108.9 M in FY2025. Personnel expenses were HUF 72.9 M (FY2025) versus HUF 78.7 M (FY2024), with the company explaining that most of this relates to IFRS 2 share-based payment accruals under the remuneration policy that have not yet been paid out. Audit fees rose from HUF 3.0 M to HUF 11.4 M. In H1 2026, SG&A fell to HUF 80.8 M (from HUF 128.7 M in H1 2025), of which HUF 57.1 M was the MRP reserve increment. Cash running costs are therefore modest (perhaps HUF 30–50 M per year, derived), but the economic cost of the MRP — dilution of outside shareholders — is substantially larger than the P&L suggests.
Equity dynamics reflect capital-structure engineering. Equity fell from HUF 5,471.5 M (start of 2024) to HUF 4,955.9 M (end of 2024) despite HUF 423.4 M of profit, because of a HUF 671.9 M capital reduction (cancellation of the "G" voting-preference series) and HUF 342.0 M of treasury-share purchases. It then rose to HUF 5,519.6 M (FY2025) and HUF 6,094.3 M (H1 2026), driven by profits plus placements to the MRP.
Balance sheet is fortress-like but concentrated. Zero debt, liabilities under 1% of equity and a current ratio above 150x. However, at YE2025 roughly 40% of total assets were in a single stock (OTP), and roughly 31% of assets were in EUR/USD deposits creating FX volatility (FY2025 FX loss on revaluation was the main financial expense). Management's own sensitivity analysis shows a ±20% move in equities would change pre-tax profit by ±HUF 465.0 M — nearly equal to an entire year's net profit.
Tax. Effective tax rate ≈ 9.0% in FY2025 (HUF 48.9 M on HUF 543.0 M), equal to the Hungarian corporate tax rate; a deferred tax asset of HUF 16.1 M on share-based payment differences was not recognised.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Single segment revenue (HUF Mn) | — | — | 0.45 | 0.45 |
Single segment operating result (HUF Mn) | — | — | -97.1 | -112.0 |
Single segment pre-tax income (HUF Mn) | 138.7 | 177.9 | 466.1 | 543.0 |
Share of total revenue (%) | — | — | 100 | 100 |
Group Entities
| Entity | Relationship | Ownership | Function | Key data |
|---|---|---|---|---|
NUTEX Befektetési Nyrt. | Parent, listed | — | Holding; IP leasing; capital allocation | Equity HUF 6,094 M (30 Jun 2026) |
NT Asset Management Vagyonkezelő Kft. | Subsidiary | 99.94% (minority: ITS GLOBAL Kft.) | Asset management (holding); holds the OTP shares since 31 Mar 2026 | Registered capital HUF 5,218 M after Jul 2026 |
NT Valoris Akvizíciós és Vagyonkezelő Kft. | Sub-subsidiary | 99.01% held by NT AM (minority: ITS GLOBAL Kft.) | Acquisition and asset-management vehicle | Founded 7 Jul 2026 with HUF 250 M; capital increased Aug and Oct 2026 |
NUTEX Nyrt. MRP Szervezet | Employee share ownership organisation | Founded by NUTEX; consolidated via IFRS "extension" method | Holds NUTEX shares for management incentive plans | 41.1 M "E" shares, 23.96% (7 Jul 2026) |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue (HUF Mn) | — | — | 0.45 | 0.45 |
Gross profit (HUF Mn) | — | — | 0.45 | 0.45 |
SG&A expenses (HUF Mn) | — | — | 97.1 | 108.9 |
Operating income (HUF Mn) | — | — | -97.1 | -112.0 |
EBITDA (HUF Mn, derived: operating result plus D&A) | — | — | -97.0 | -111.7 |
Net financial result (HUF Mn) | — | — | 563.3 | 655.0 |
Pre-tax income (HUF Mn) | 138.7 | 177.9 | 466.1 | 543.0 |
Income tax (HUF Mn) | — | — | 42.7 | 48.9 |
Net income (HUF Mn) | 133.5 | 171.1 | 423.4 | 494.2 |
EPS basic (HUF) | — | — | 2.84 | 3.80 |
EPS diluted (HUF) | — | — | 2.54 | 3.40 |
Dividends per share (HUF) | — | 0 | 0 | 0 |
Dividends & Capital Returns
| Metric | FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Financial income total (HUF Mn) | 563.3 | 855.9 | 342.0 | 728.4 |
Dividends received (HUF Mn) | 74.9 | 70.2 | 70.2 | 73.6 |
Interest received (HUF Mn) | 3.3 | 18.2 | 13.5 | 1.0 |
Financial expenses total (HUF Mn) | 0.0 | 200.8 | 83.2 | 129.9 |
of which unrealised FX losses (HUF Mn) | — | — | 83.2 | 94.2 |
Net financial result (HUF Mn) | 563.3 | 655.0 | 258.8 | 598.5 |
Income Statement and Per-Share Data (Half-Yearly)
| Metric | H1 2022 | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|---|
Net income (HUF Mn) | 35.7 | -24.8 | 267.9 | 115.4 | 517.7 |
Pre-tax income (HUF Mn) | — | — | — | 130.4 | 517.9 |
Operating result (HUF Mn) | — | — | — | -128.5 | -80.6 |
EPS basic (HUF) | — | — | — | 0.89 | 3.98 |
Balance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (HUF Mn) | 5,480.3 | 4,998.4 | 5,555.3 |
Cash and equivalents (HUF Mn) | 2,151.3 | 1,905.7 | 2,253.6 |
Short-term investments (HUF Mn) | — | 2,867.6 | 3,120.5 |
Other non-trade receivables (HUF Mn) | — | 224.2 | 180.5 |
Short-term debt (HUF Mn) | 0 | 0 | 0 |
Long-term debt (HUF Mn) | 0 | 0 | 0 |
Net debt (HUF Mn, cash only) | -2,151.3 | -1,905.7 | -2,253.6 |
Total equity (HUF Mn) | 5,471.5 | 4,955.9 | 5,519.6 |
Goodwill and intangibles (HUF Mn) | 0 | 0 | 0 |
Current liabilities (HUF Mn) | — | 42.4 | 35.7 |
Working capital (HUF Mn) | — | 4,955.8 | 5,519.3 |
Asset Portfolio
| Asset | FY2025 value (HUF Mn) | Share of total assets (%) | Valuation level |
|---|---|---|---|
Bank deposits and cash | 2,253.6 | 40.6 | Amortised cost |
OTP Bank shares | 2,248.1 | 40.5 | Level 1 |
Erste Euro Real Estate Fund units | 548.3 | 9.9 | Level 2 |
Hungarian government securities | 247.3 | 4.5 | Level 2 |
Other receivables (incl. govt bond sale proceeds) | 180.5 | 3.2 | Amortised cost |
MOL shares | 57.5 | 1.0 | Level 1 |
Richter shares | 19.4 | 0.3 | Level 1 |
Tangible assets and other | 0.7 | 0.0 | Cost |
Total | 5555.3 | 100.0 | — |
Cash Flow
| Metric | FY2024 | FY2025 |
|---|---|---|
Operating cash flow (HUF Mn) | -122.1 | 256.3 |
Capex (HUF Mn) | -0.2 | -0.4 |
Free cash flow (HUF Mn, derived) | -122.3 | 255.9 |
Dividends paid (HUF Mn) | 0 | 0 |
Share buybacks (HUF Mn) | 342.0 | 0 |
Net change in cash (HUF Mn) | -245.5 | 347.8 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE (%, derived, average equity) | — | 8.1 | 9.4 |
ROA (%, derived, average assets) | — | 8.1 | 9.4 |
Current ratio (x) | — | 117.8 | 155.5 |
Debt to equity (x) | 0 | 0 | 0 |
Liabilities to equity (%) | — | 0.86 | 0.65 |
Asset turnover (x, derived) | — | 0.0001 | 0.0001 |
Share Count (M)
| Metric | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
Shares outstanding incl. F series (M) | 148.15 | 158.45 | 171.25 |
Book value per share (HUF, derived, parent equity / total shares) | 33.5 | 34.8 | 35.6 |
Weighted avg shares basic (M) | 149.0 | 130.1 | — |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
Hungary (HUF Mn) | 0.45 | 0.45 |
Rest of world (HUF Mn) | 0 | 0 |
Segment Overview
| Segment | Hungary share (%) | Other share (%) |
|---|---|---|
Asset utilisation / IP leasing (single segment) | 100 | 0 |
Exposure Details
| Exposure | Approx. value (HUF Mn) | Basis |
|---|---|---|
Hungarian listed equities (OTP, MOL, Richter) | 2,325.0 | 2025 Annual Report, Note 9 |
Hungarian government securities | 247.3 | 2025 Annual Report, Note 9 |
EUR deposits | ≈1451 | Derived from ±10% EUR/HUF sensitivity of ±HUF 145.1 M |
USD deposits | ≈262 | Derived from ±10% USD/HUF sensitivity of ±HUF 26.2 M |
EUR real-estate fund (euro-area property) | 548.3 | 2025 Annual Report, Note 9 |
HUF cash (residual, derived) | ≈540 | Total cash less derived FX deposits |
Share Price History
| Date | Price (HUF) | Context | Source |
|---|---|---|---|
Jun 2023 | 8 → 16 | Graboplast speculation | Világgazdaság (Jan 2026 retrospective) |
6 Dec 2024 | 17.8 | Close before dividend proposal | Világgazdaság, Dec 2024 |
9 Dec 2024 | 22.9 intraday (+29%) | HUF 25 dividend proposal | Világgazdaság, Dec 2024 |
Dec 2024 | up to 27 | Peak of dividend speculation | Világgazdaság (Jan 2026 retrospective) |
Jan 2025 | 24 | Issue price of MRP placement | 2025 Annual Report |
26 Jan 2026 | 13.60 → 14.60 | Retail speculation | Világgazdaság, Jan 2026 |
Jun 2026 | 13 → 13.7 | Morvai stake disclosure | Világgazdaság, Jun 2026 |
21 Jun 2026 | 14.3 | Issue price of MRP placement (≈ last close) | H1 2026 Report |
23 Jul 2026 | 12.7 | — | Világgazdaság price widget |
16 Oct 2026 | 12.4 | Latest available | Világgazdaság price widget |
Historic | 12,200 | All-time high (pre-restructuring basis) | Világgazdaság, 2017 |
Share Price & Returns
| Horizon | Return | Basis |
|---|---|---|
Since Dec 2024 peak (HUF 27) | ≈ -54% (derived) | Derived |
Valuation Multiples
| Multiple | NUTEX | Basis |
|---|---|---|
Market cap (HUF Mn) | 2,123 | 171.2 M listed shares × HUF 12.4 |
P/E (FY2025) | 4.3x | Market cap / FY2025 net income HUF 494.2 M |
P/E (TTM to Jun 2026) | 2.4x | Market cap / TTM net income ≈ HUF 896.5 M |
P/B | ≈0.35x | Market cap / parent equity HUF 6,090.8 M (30 Jun 2026) |
EV (HUF Mn) | ≈ -205 | Market cap less cash HUF 2,327.7 M (no debt); EV is negative even before counting the HUF 3.5 bn securities portfolio |
Cash + securities per share (HUF, derived) | ≈34.2 | (2,327.7 + 3,535.5) / 171.25 M shares |
Capital Markets
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Dividend per share (HUF) | 0 | 0 | 0 |
Dividends paid (HUF Mn) | — | 0 | 0 |
Capital Markets — FY2024 repurchase
| Item | Detail |
|---|---|
FY2024 repurchase | 18 M shares for HUF 342 M (≈ HUF 19/share), subsequently transferred to MRP (Jan 2025) |
Current authorisations | Up to 25% of share capital in treasury, 18-month term (granted 28 Apr, 28 May, 26 Jun 2026); price HUF 1 to 1.5x prior-year BVPS (ordinary) or up to 10x BVPS (preference shares); also call-option-based repurchases |
Purchases since last AGM | None, per company disclosures at the May and June 2026 meetings |
Credit Ratings
| Agency | Rating |
|---|---|
Moody's | Not rated |
S&P | Not rated |
Fitch | Not rated |
Analyst Conclusions
Management guidance
None provided. Management's only forward-looking statements concern the going-concern conclusion and the continued pursuit of acquisitions via NT Asset Management and NT Valoris.
Consensus expectations
No sell-side consensus exists. Mechanically, FY2026 earnings will be determined by year-end marks on OTP shares and the EUR/USD-to-HUF exchange rates; H1 2026 net income of HUF 517.7 M sets a high base.
Bull case
-
Deep asset backing: cash plus liquid securities of ≈ HUF 34 per share (derived, 30 Jun 2026) versus a HUF 12.4 share price — even a substantial haircut to OTP still leaves a large margin of safety on paper.
-
Transaction optionality: a fully built acquisition chain, HUF 60–70 bn authorisations and a new >5% holder with a healthcare background point to a potential transformative deal that could re-rate the shares, as seen in the Graboplast (2023) and dividend (2024) episodes when the price doubled or rose ~50%.
-
Compounding NAV: four consecutive profitable years and record H1 2026 earnings (HUF 517.7 M) with negligible cash costs and no debt.
Bear case
-
Minority value leakage: repeated below-book share issuance to a company-funded MRP (HUF 24, then HUF 14.3 per share), plus authorisation for ≥32 M more shares, transfers NAV per share from outside holders to insiders; the discount to NAV may be rational rather than an anomaly.
-
Control entrenchment: MRP at 23.96%, deferred removal of voting caps, and authorised 10x-voting unlisted preference shares could make management effectively unremovable and decouple voting control from economic ownership.
-
Concentrated, volatile NAV and regulatory overhang: ≈40% of assets in OTP and ≈31% in FX deposits; MNB fine and legality-supervision history; no assurance any acquisition will be accretive.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters |
|---|---|
| Announcement of a first acquisition via NT Valoris | Determines whether NUTEX becomes an operating company and at what dilution |
| Further MRP share acquisitions (≥32 M shares authorised) | Dilution and control concentration |
| Any issuance of new 10x-voting preference shares | Governance red flag |
| Decision on voting-cap removal (repeatedly deferred) | Control dynamics |
| Outcome of the MNB-initiated Court of Registration proceeding | Regulatory and governance risk |
| OTP share price and dividends | Primary NAV and earnings driver |
| EUR/HUF and USD/HUF exchange rates | FX gains/losses on ≈ HUF 1.7 bn deposits |
| FY2026 Annual Report (expected late April 2027) and dividend decision | Cash return to shareholders |
| Stance of significant shareholders (Morvai, historic holders) at general meetings | Potential resistance to, or support for, management proposals |
Analyst verdict
NUTEX is best understood not as a pharmaceutical or consumer-health company — the label many data vendors still attach to it — but as a debt-free Hungarian investment shell whose roughly HUF 6.1 bn of assets consist almost entirely of bank deposits, OTP Bank shares, government paper and a euro real-estate fund. On a pure asset basis, the stock is strikingly cheap: at HUF 12.4 it trades at about 0.35x book value, below its cash balance alone, at roughly 2–4x earnings, with negative enterprise value.
The discount, however, is not a market inefficiency waiting to close by itself. The company's earnings are mark-to-market gains it does not distribute; it has declined to pay dividends for at least three consecutive years, including rejecting a shareholder-proposed HUF 25 per share payout in December 2024. Meanwhile, it has used company cash to fund an employee share ownership vehicle that has acquired nearly a quarter of the voting shares at prices well below book value, and shareholders have authorised capital increases of up to HUF 70 bn, further MRP accumulation and unlisted 10x-voting preference shares. The MNB has fined and warned the company and challenged the conduct of its December 2024 general meeting. For an outside investor, the critical question is therefore whose interests the eventual capital deployment will serve.
The most plausible paths are: (i) a large in-kind acquisition or reverse listing that transforms NUTEX, the value of which to current minorities will depend entirely on deal terms; or (ii) continued accumulation of NAV alongside incremental dilution. A shareholder-friendly outcome — a tender offer, large buyback or special dividend near NAV — is possible but not signalled.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / other positions | Compensation (latest) |
|---|---|---|---|---|
Gábor Sándor Csereklei | CEO (vezérigazgató); Board member (via CS Trade Kft. since 3 Jun 2025); Investor Relations | CEO start date not publicly disclosed | Managing director of CS Trade Kft.; managing-director representative of ITS GLOBAL Kft. at NT Asset Management Kft. and NT Valoris Kft. | Monthly gross salary HUF 266,800 to 31 Aug 2025; HUF 320,000 from 1 Sep 2025; HUF 322,800 in H1 2026. Annualised ≈ HUF 3.9 M (derived). Participant in MRP share-based plans (value not separately disclosed) |
Board of Directors
| Member | Role | Since | Represented by | Independence | Remuneration |
|---|---|---|---|---|---|
CS Trade Kft. | Board member | 3 Jun 2025 (indefinite term) | Gábor Sándor Csereklei (managing director of CS Trade) | Executive / not independent | None for board role |
RNT Holding Zrt. | Board member | 3 Jun 2025 (indefinite term) | Szabolcs File (CEO of RNT Holding) | Listed as independent director (Investing.com shows File Szabolcs as independent since 2022) | None for board role |
Dóra Kopros | Board member | — | — | Independent (per Investing.com) | None for board role |
Viola Vargha | Board member | — | — | Independent (per Investing.com) | None for board role |
Anikó Varghané Barta | Board member | — | — | Independent (per Investing.com) | None for board role |
“—” = not publicly disclosed.
Governance Timeline
| Date | Transaction | Shares / amount |
|---|---|---|
Nov–Dec 2024 | NUTEX buys 18 M own shares (≈ HUF 19 each, HUF 342 M total) | 18,000,000 |
15 Jan 2025 | 18 M treasury shares transferred to MRP | 18,000,000 |
20 Jan 2025 | Cash contribution from NUTEX to MRP | HUF 250 M |
21 Jan 2025 | Private placement to MRP at HUF 24/share | 10,300,000 (HUF 247.2 M) |
31 Dec 2025 | MRP holding | 28,300,000 |
18 Jun 2026 | Cash contribution from NUTEX to MRP | HUF 265 M |
21 Jun 2026 | Private placement to MRP at HUF 14.3/share | 12,800,000 (HUF 183.0 M) |
7 Jul 2026 | MRP holding | 41,100,000 (23.96%) |
28 May / 26 Jun 2026 | AGM resolutions: fund MRP to acquire at least 32,000,000 further shares | ≥32,000,000 (pending) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
3 Jun 2025 | RNT Holding Zrt. (Szabolcs File) and CS Trade Kft. (Gábor Csereklei) elected to board | Conversion of individual board seats to legal-entity seats |
1 Sep 2025 | CEO salary raised from HUF 266,800 to HUF 320,000 per month | 2025 Annual Report |
2025–2026 | Multiple amendments to remuneration policy (AGMs of 19 May 2025, 28 May 2026, 19 Jun 2026, 26 Jun 2026) | Expansion of MRP |
25 Aug 2026 | ITS GLOBAL Kft. (represented by Csereklei) appointed managing director of NT Valoris | Acquisition vehicle set-up |
Major Shareholders
| Holder | Stake | Date / source | Notes |
|---|---|---|---|
NUTEX Nyrt. MRP Szervezet | 23.96% (41,100,000 shares) | 7 Jul 2026, H1 2026 Report | Treated as treasury shares under IFRS extension method |
Dr. László Morvai |
| Jun 2026, Világgazdaság | Managing director of SOS Medical (Szeged-based GP and outpatient care provider) |
Huber István | Not current; was >15% in 2017 | Világgazdaság 2017; company offered to buy 10 M (+10 M option) of his shares in Nov 2024 | Co-initiator of December 2024 EGM |
Holba Sándor Imre | — | Co-initiator of December 2024 EGM (Világgazdaság) | — |
Raltex Ltd. | — | Világgazdaság 2017 | Historic largest holder |
Remich Continental | — | Világgazdaság 2017 | Historic |
Galamb Vilmos | — | Világgazdaság 2017 | Historic |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Company | Ticker (BÉT) | Profile | Market cap (latest available) | Relevance |
|---|---|---|---|---|
ENEFI Vagyonkezelő Nyrt. | ENEFI | Small asset manager / thermal energy (Hungary, Cyprus, Romania) | ≈ HUF 2.4 bn (Simply Wall St, undated) | Closest size peer; former operating company turned asset manager |
Forrás Nyrt. | FORRAS | Small holding / asset management | — | Shell-like holding peer |
OPUS GLOBAL Nyrt. | OPUS | Diversified holding (construction, industry, energy, tourism) | ≈ HUF 255.4 bn (Simply Wall St, undated) | Large holding company benchmark |
Budapesti Ingatlan Hasznosítási és Fejlesztési Nyrt. (BIF) | BIF | Real-estate holding | — | Asset-backed holding peer |
Ormester Vagyonvédelmi Nyrt. | ORMESTER | Security services | ≈ HUF 0.98 bn (Simply Wall St, undated) | Micro-cap Budapest peer |
Budapest Stock Exchange (Budapesti Értéktőzsde) | BET | Exchange operator | ≈ HUF 38.7 bn (Simply Wall St, undated) | Micro/small-cap Budapest reference |
OTP Bank Nyrt. | OTP | Largest holding of NUTEX (≈40% of assets) | — | Primary NAV driver |
MOL Nyrt. | MOL | Oil and gas; small NUTEX holding | ≈ HUF 1.7–2.5 trn (Simply Wall St snapshots) | Portfolio holding |
Gedeon Richter Nyrt. | RICHTER | Pharmaceuticals; small NUTEX holding; reference for NUTEX's former pharma identity | ≈ HUF 2.2 trn (Simply Wall St, undated) | Portfolio holding / legacy sector benchmark |
Nutex Health Inc. (US) | NASDAQ: NUTX | Unrelated US healthcare company | — | Name-confusion risk only |
Peer Comparison FY2025
| Metric | NUTEX (FY2025) | ENEFI | OPUS GLOBAL |
|---|---|---|---|
Revenue (HUF Mn) | 0.45 | — | — |
Revenue growth (%) | 0 | — | — |
Net income (HUF Mn) | 494.2 | — | — |
Market cap (HUF Bn) | ≈2.1 | ≈2.4 | ≈255.4 |
R&D intensity (%) | 0 | — | — |



